Figure 5
From: SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
Effects of bortezomib and AZD1775+midostaurin combination in HMC-1 cells. (a and b) reduction of clonogenic growth of HMC-1.1 (red curve) and -1.2 (blue curve) cells, in the presence of increasing doses of bortezomib (0.25–1 nm) and AZD1775+midostaurin (0.025–0.1 μm), respectively. All the clonogenic survival rates are expressed as mean±standard deviation of counts from three independent experiments. Curves with AZD1775 (0.025–0.1 μm) and midostaurin (0.025–0.1 μm) as single agents are shown in c and d. (e) comparison of LD50 values for the different strategies. (f and g) Induction of apoptosis in HMC-1.1 and -1.2, respectively. Columns represent the mean of three independent experiments and the bars represent the standard error. ctrl, control; mido, midostaurin.
